Topic: influenza

The number of flu shots that passed Chinese regulators so far this season has fallen about 19%, leaving the country short on needed supplies.

Johnson & Johnson has big ambitions in vaccines, and to get there, its manufacturing capacity has to measure up.

Roche hopes the single-dose flu drug can squeeze out some generic competition to Tamiflu.

Here is some other vaccine news of note for the week.

While Seqirus works to boost manufacturing for its cell-based flu vaccine in the U.S., the shot is nearing an approval in Europe.

Seqirus says it is phasing delivery of its flu vaccine Fluad to the U.K. ahead of the peak season, though pharmacists have reported a lack of supply.

Seqirus published data showing that cell-derived flu viruses matched better with circulating strains than egg-based counterparts.

Vaxart touted phase 2 data for its oral flu vaccine candidate in a trial against Sanofi's market-leading Fluzone.

Through an ongoing "challenge" study, FluGen hopes to see whether the nasal vaccine can fight off the flu virus that doesn't match its own.

Xofluza only showed numerical reduction in time to symptom improvement compared with Tamiflu in complicated flu patients.